Bristol Myers’ Opdivo improved overall survival in resectable NSCLC, per final Phase 3 data. The study confirms its benefit when combined with chemotherapy.
Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer
